PMID- 27110135
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160425
LR  - 20201001
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 9
DP  - 2016
TI  - Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on 
      hemodialysis.
PG  - 65-71
LID - 10.2147/IJGM.S102070 [doi]
AB  - BACKGROUND: Cardiovascular disease (CVD) is the main cause of death among 
      hemodialysis (HD) patients. The effects of the dipeptidyl peptidase-4 inhibitor 
      teneligliptin on CVD-related biomarkers in patients with type 2 diabetes mellitus 
      (T2DM) receiving HD treatment are poorly understood. To determine whether 
      teneligliptin has anti-CVD properties, we assessed its effects on soluble 
      P-selectin (sP-selectin), platelet-derived microparticles (PDMPs), plasminogen 
      activator inhibitor 1 (PAI-1), soluble E-selectin (sE-selectin), soluble vascular 
      adhesion molecule 1 (sVCAM-1), and adiponectin plasma levels in HD and non-HD 
      patients with T2DM. METHODS: Patients with T2DM eligible for teneligliptin 
      monotherapy or combination therapy (eg, teneligliptin plus a sulfonylurea) were 
      administered teneligliptin (20 mg/d) once daily for 6 months. Plasma levels of 
      sP-selectin, PDMPs, PAI-1, sE-selectin, sVCAM-1, and adiponectin were measured by 
      enzyme-linked immunosorbent assay at baseline and after 3 months and 6 months of 
      treatment. RESULTS: Teneligliptin therapy significantly reduced plasma levels of 
      sP-selectin, PDMPs, and PAI-1 compared with baseline levels, while significantly 
      increasing adiponectin levels. sE-selectin and sVCAM-1 levels were significantly 
      decreased only at 6 months. The reduction in sP-selectin, PDMPs, and PAI-1 was 
      more significant in HD patients than in non-HD patients. However, the improvement 
      in adiponectin levels was unchanged with HD treatment. CONCLUSION: By modulating 
      PDMPs or PAI-1, teneligliptin shows an antiatherothrombotic effect that may be 
      beneficial in the primary prevention of CVD in patients with T2DM on HD.
FAU - Okuda, Yoshinori
AU  - Okuda Y
AD  - Division of Internal Medicine, Meisei Memorial Hospital, Osaka, Japan.
FAU - Omoto, Seitaro
AU  - Omoto S
AD  - Division of Internal Medicine, Kohrigaoka Yukeikai Hospital, Osaka, Japan.
FAU - Taniura, Takehito
AU  - Taniura T
AD  - Division of Internal Medicine, Daiwa Hospital, Osaka, Japan.
FAU - Shouzu, Akira
AU  - Shouzu A
AD  - Division of Internal Medicine, Saiseikai Izuo Hospital, Osaka, Japan.
FAU - Nomura, Shosaku
AU  - Nomura S
AD  - First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160412
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC4835142
OTO - NOTNLM
OT  - PAI-1
OT  - PDMP
OT  - hemodialysis
OT  - teneligliptin
OT  - type 2 diabetes mellitus
EDAT- 2016/04/26 06:00
MHDA- 2016/04/26 06:01
PMCR- 2016/04/12
CRDT- 2016/04/26 06:00
PHST- 2016/04/26 06:00 [entrez]
PHST- 2016/04/26 06:00 [pubmed]
PHST- 2016/04/26 06:01 [medline]
PHST- 2016/04/12 00:00 [pmc-release]
AID - ijgm-9-065 [pii]
AID - 10.2147/IJGM.S102070 [doi]
PST - epublish
SO  - Int J Gen Med. 2016 Apr 12;9:65-71. doi: 10.2147/IJGM.S102070. eCollection 2016.